HI HB667

Requires patients and prescribers to execute a written informed consent agreement for opioid therapy when treatment exceeds three months, benzodiazepines and opioids are prescribed together, or doses exceed 90 morphine equivalent doses.

Mandates the informed consent agreement include discussion of overdose risks, naloxone co-prescribing, non-opioid alternatives, functional treatment goals, risk assessments, urine drug screening at least twice yearly, and psychiatric consultation if therapy continues beyond six months.

Limits initial prescriptions for opioids and benzodiazepines to a maximum of seven consecutive days, except for cancer treatment, palliative care, or hospice care patients.

Requires prescribers to document in medical records the medical condition justifying prescriptions exceeding seven days and confirm that non-opioid alternatives are not appropriate treatment.

Directs the state administrator to develop a template for the opioid therapy informed consent agreement for statewide use.